| 抗EGFR单抗在转移性结直肠癌中耐药机制的研究进展 |
| |
| 引用本文： | 惠俊俊,杨 觅,李 丽,胡 静,刘宝瑞,钱晓萍. 抗EGFR单抗在转移性结直肠癌中耐药机制的研究进展[J]. 现代肿瘤医学, 2018, 0(12): 1950-1954. DOI: 10.3969/j.issn.1672-4992.2018.12.038 |
| |
| 作者姓名： | 惠俊俊 杨 觅 李 丽 胡 静 刘宝瑞 钱晓萍 |
| |
| 作者单位： | 南京大学医学院附属鼓楼医院肿瘤中心，江苏 南京 210008 |
| |
| 基金项目： | 江苏省卫计委发展项目（编号:H2017042）；南京市省级自然科学基金（编号:BK20161107）；南京市科技发展计划项目（编号:201503013） |
| |
| 摘 要： | 抗表皮生长因子受体（EGFR）单克隆单抗分子靶向药物在转移性结直肠癌中的应用，显著改善了患者无进展生存期及总生存期，由于迅速产生继发性耐药限制了其临床运用效果。因此，寻找生物标志物初步筛选敏感人群及预测耐药，以及研究分子靶向药物耐药机制的产生以逆转耐药，都是进一步提高转移性结直肠癌治疗效果的关键，目前靶向药物联合应用有望进一步提高治疗有效率并逆转耐药。
|
| 关 键 词： | 结直肠癌 EGFR 耐药 |
Research progress of resistance mechanisms and restoring sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer |
| |
| Hui Junjun,Yang Mi,Li Li,Hu Jing,Liu Baorui,Qian Xiaoping. Research progress of resistance mechanisms and restoring sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer[J]. Journal of Modern Oncology, 2018, 0(12): 1950-1954. DOI: 10.3969/j.issn.1672-4992.2018.12.038 |
| |
| Authors: | Hui Junjun Yang Mi Li Li Hu Jing Liu Baorui Qian Xiaoping |
| |
| Affiliation: | The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University，& Clinical Cancer Institute of Nanjing University,Jiangsu Nanjing 210008，China. |
| |
| Abstract: | Epidermal growth factor receptor(EGFR) targeted monoclonal antibodies are effective in a subset of solid tumors incuding metastatic colorectal cancer.While patients develop drug resistance rapidly that limits these agents further clinical treatment.It is important to evalute molecular markers identifying those who are more likely to respond,and it is critical to understand the mechanisms of resistance to targeted therapies.Incorporation of targeted agents has been expected to develop novel therapeutic strategies improving efficacy of colorectal cancer treatment and restoring their drug sensitivity. |
| |
| Keywords: | colorectal cancer EGFR drug resistance |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
